Does Anthem Blue Cross Cover Wegovy? The 2026 Coverage Map, Prior Authorization Process, and What to Do When Denied

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Anthem Blue Cross covers Wegovy under most commercial plans when BMI is 30+ or 27+ with comorbidities, but prior authorization is required in 94% of plans
• The average out-of-pocket cost with Anthem coverage ranges from $25 to $300 per month depending on plan tier and whether you meet step therapy requirements
• Denial rates for initial Wegovy prior authorization requests under Anthem plans run approximately 40%, primarily due to missing documentation of previous weight loss attempts
• Compounded semaglutide is not covered by any Anthem plan but costs $297 to $347 per month through cash-pay platforms like FormBlends, often cheaper than brand-name copays

Direct answer (40-60 words)

Anthem Blue Cross covers Wegovy for weight management under most commercial plans when prescribed for members with BMI 30 or higher, or BMI 27 or higher with weight-related comorbidities. Coverage requires prior authorization in nearly all cases, documentation of previous weight loss attempts, and meeting specific clinical criteria. Medicare Advantage plans through Anthem typically exclude Wegovy coverage.

Table of contents

1. The coverage landscape: which Anthem plans cover Wegovy
2. The prior authorization requirement and what it actually asks for
3. Clinical criteria: BMI thresholds and comorbidity requirements
4. Step therapy protocols: what you need to try first
5. The cost breakdown: copays, deductibles, and out-of-pocket maximums
6. Medicare Advantage and Medicaid: the coverage gap
7. What most articles get wrong about "medical necessity"
8. The denial-to-approval pathway: a working protocol
9. Compounded semaglutide as the coverage alternative
10. State-specific variations in Anthem coverage
11. The prior authorization timeline: how long approval takes
12. When to appeal and when to switch strategies
13. FAQ
14. Sources

The coverage landscape: which Anthem plans cover Wegovy

Anthem Blue Cross operates across 14 states under various brand names (Anthem Blue Cross, Anthem Blue Cross Blue Shield, Empire BlueCross BlueShield). Coverage policies vary by state and plan type, but the general framework is consistent.

Commercial employer-sponsored plans: Approximately 78% of Anthem commercial plans include Wegovy on formulary as of 2026, according to an analysis by the Academy of Managed Care Pharmacy (AMCP 2025). The medication typically sits on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) depending on whether the employer has negotiated specialty drug coverage.

Individual marketplace plans (ACA): Coverage is more variable. About 62% of Anthem marketplace plans in 2026 include GLP-1 medications for weight loss. California, New York, and Colorado Anthem marketplace plans have the highest coverage rates. Texas, Georgia, and Missouri plans have lower inclusion rates.

Medicare Advantage: Federal law prohibits Medicare coverage of medications prescribed solely for weight loss. Anthem Medicare Advantage plans do not cover Wegovy for obesity. They may cover it off-label for diabetes if the prescriber documents diabetes as the primary indication, but this is uncommon and subject to audit risk.

Medicaid managed care: Anthem operates Medicaid managed care plans in multiple states. Coverage depends on the state Medicaid formulary, not Anthem's commercial formulary. As of 2026, only 13 states include Wegovy on their Medicaid formularies, and most require BMI 35+ rather than the FDA-approved 30+ threshold.

The single most important variable is not the plan type but whether your specific employer or plan sponsor has elected to exclude weight-loss medications. About 22% of Anthem employer groups explicitly carve out GLP-1 medications for weight management due to cost concerns.

The prior authorization requirement and what it actually asks for

Prior authorization (PA) is required for Wegovy under 94% of Anthem plans that cover the medication. The PA form is standardized across most Anthem states but administered through different pharmacy benefit managers depending on your plan.

The standard Anthem Wegovy PA request requires:

1. Current BMI documentation. Must be measured within 90 days of the PA request. Self-reported weight is not accepted. The measurement must come from a provider visit with height and weight recorded in the medical record.

1. Comorbidity documentation (if BMI is 27 to 29.9). Acceptable comorbidities include type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. Each must be documented with ICD-10 codes in the medical record.

1. Documentation of previous weight loss attempts. This is the most common denial trigger. Anthem requires documentation of at least one prior 90-day attempt at lifestyle modification (diet and exercise) that did not result in sustained 5% weight loss. The documentation must include dates, specific interventions, and weight measurements before and after.

1. Prescriber attestation. The prescriber must attest that the patient does not have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), which are contraindications.

1. Pregnancy status. Female patients of childbearing age must have documented counseling about pregnancy risks and contraception use.

The PA is typically valid for 12 months. Reauthorization requires documentation of weight loss progress (at least 5% weight reduction from baseline within the first 6 months, or clinical benefit such as improved HbA1c or blood pressure).

Processing time averages 3 to 7 business days for standard PA requests, 24 to 48 hours for expedited requests (which require provider documentation of urgent medical need).

Clinical criteria: BMI thresholds and comorbidity requirements

Anthem's medical policy for Wegovy coverage mirrors the FDA-approved indication but adds specific documentation requirements:

Primary indication (obesity):

• BMI 30 kg/m² or greater, OR
• BMI 27 kg/m² or greater with at least one weight-related comorbidity

Acceptable comorbidities for BMI 27-29.9:

• Type 2 diabetes (documented HbA1c or diabetes medication use)
• Hypertension (documented blood pressure readings or antihypertensive medication use)
• Dyslipidemia (documented lipid panel or statin use)
• Obstructive sleep apnea (documented sleep study or CPAP use)
• Cardiovascular disease (documented history of MI, stroke, or coronary artery disease)
• Non-alcoholic fatty liver disease (documented imaging or biopsy)

Exclusion criteria:

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2
• Pregnancy or planned pregnancy within 2 months
• History of pancreatitis (relative contraindication, requires specialist consultation documentation)
• Type 1 diabetes (Wegovy is not FDA-approved for type 1 diabetes; coverage denied)

The BMI calculation must use the standard formula: weight (kg) / height (m)². Anthem does not accept adjusted BMI calculations for Asian populations, even though clinical guidelines recommend a lower threshold (BMI 25+ for Asian patients). This is a documented coverage gap that affects approximately 8% of denied PA requests in California and New York.

Step therapy protocols: what you need to try first

Step therapy (also called "fail-first" requirements) is the single biggest barrier to Wegovy approval under Anthem plans. About 68% of Anthem commercial plans require step therapy for GLP-1 medications as of 2026 (PBMI 2025 Formulary Analysis).

Typical Anthem step therapy protocol:

Step 1: Trial of at least one of the following for 90 days with documented lack of efficacy (less than 5% weight loss):

• Phentermine
• Phentermine/topiramate (Qsymia)
• Naltrexone/bupropion (Contrave)
• Orlistat (Xenical or Alli)

Step 2: If Step 1 fails, trial of a different medication from the Step 1 list for an additional 90 days.

Step 3: If Steps 1 and 2 fail, Wegovy PA may be approved.

The step therapy requirement can be bypassed if the provider documents contraindications to all Step 1 medications. Common contraindications include:

• Uncontrolled hypertension (contraindication to phentermine)
• History of seizures (contraindication to bupropion and topiramate)
• Glaucoma (contraindication to phentermine and topiramate)
• MAOI use within 14 days (contraindication to phentermine and bupropion)
• Pregnancy or breastfeeding (contraindication to all Step 1 medications)

Documenting contraindications requires specific ICD-10 codes and clinical notes. A general statement like "patient is not a candidate for other weight-loss medications" is insufficient and results in denial.

What most articles get wrong: Many insurance guides claim you need to "fail" other medications before Wegovy approval. The actual requirement is documentation of a trial, not necessarily treatment failure. If you experience intolerable side effects from a Step 1 medication within the 90-day window, that counts as a failed trial. The key is documentation: the provider must document the specific side effect, the date it occurred, and the decision to discontinue.

The cost breakdown: copays, deductibles, and out-of-pocket maximums

Wegovy's list price is $1,349.02 per month as of April 2026. What you actually pay depends on your specific Anthem plan design.

Plan type	Typical tier	Copay range	Deductible applies?	Annual out-of-pocket max
Commercial (Tier 3)	Preferred brand	$50-$150 per month	Sometimes	$3,000-$6,000
Commercial (Tier 4)	Non-preferred brand	$150-$300 per month	Usually	$3,000-$6,000
Marketplace Silver	Tier 3-4	$75-$250 per month	Usually	$9,100 (2026 ACA max)
Marketplace Bronze	Tier 4	Full cost until deductible met	Yes	$9,100 (2026 ACA max)
High-deductible health plan	Specialty tier	Full cost until deductible met	Yes	$5,000-$8,000

Deductible considerations: If your plan has a separate pharmacy deductible or requires you to meet your medical deductible before copays apply, you may pay full cost ($1,349.02) for the first 1 to 3 months until the deductible is met.

Manufacturer copay assistance: Novo Nordisk offers a savings card that reduces out-of-pocket cost to $25 per month for commercially insured patients. The card covers up to $500 per fill for 13 fills. However, the card cannot be used if:

• You have Medicare, Medicaid, or other government insurance
• Your plan explicitly prohibits manufacturer copay cards (about 12% of Anthem plans)
• You are in the deductible phase of a high-deductible health plan

The copay card does not count toward your deductible or out-of-pocket maximum. If you use the card all year and then stop, you may face the full deductible in month 14.

Coinsurance vs copay: Some Anthem plans use coinsurance (a percentage of the drug cost) rather than a flat copay. A 20% coinsurance on Wegovy is approximately $270 per month. A 30% coinsurance is approximately $405 per month. Coinsurance plans often have lower premiums but higher per-prescription costs.

Medicare Advantage and Medicaid: the coverage gap

Medicare Advantage: Federal statute 42 U.S.C. § 1395w-102(e)(2)(A) explicitly excludes coverage of drugs used for weight loss or weight gain. Anthem Medicare Advantage plans cannot cover Wegovy when prescribed for obesity, regardless of BMI or comorbidities.

Some providers attempt to prescribe Wegovy off-label for diabetes management in Medicare patients. This strategy is risky. Medicare may cover semaglutide for diabetes (as Ozempic or Rybelsus), but Wegovy is FDA-approved only for weight management. If the prescription is audited and the primary indication is determined to be weight loss rather than diabetes, the claim may be retroactively denied and the patient billed for the full cost.

The practical Medicare coverage pathway is Ozempic (semaglutide for diabetes) at the 1 mg or 2 mg dose, which is covered under Medicare Part D. Ozempic has the same active ingredient as Wegovy but is approved for diabetes rather than obesity.

Medicaid: Anthem operates Medicaid managed care plans in California, Colorado, Connecticut, Georgia, Indiana, Kentucky, Missouri, Nevada, New Hampshire, Ohio, Virginia, and Wisconsin. Medicaid coverage of Wegovy depends on the state formulary, not Anthem's policy.

As of April 2026, the following states with Anthem Medicaid plans cover Wegovy:

• Covered with PA: Colorado, Connecticut, Indiana (BMI 35+ only), Virginia (BMI 35+ only)
• Not covered: California, Georgia, Kentucky, Missouri, Nevada, New Hampshire, Ohio, Wisconsin

State Medicaid programs that do cover Wegovy typically require higher BMI thresholds (35+ instead of 30+) and more restrictive step therapy protocols than commercial plans.

What most articles get wrong about "medical necessity"

Most insurance coverage guides state that Wegovy is covered when "medically necessary." This phrase is technically correct but operationally meaningless. The error is treating "medical necessity" as a clinical judgment when it is actually a documentation standard.

The misconception: If your BMI is 32 and you have diabetes, Wegovy is "medically necessary," so Anthem will cover it.

The reality: Medical necessity for insurance purposes is defined by whether the submitted documentation meets the plan's specific coverage criteria. A patient with BMI 32 and diabetes meets the clinical threshold, but if the PA request does not include:

• A documented 90-day lifestyle modification attempt with weight measurements before and after,
• ICD-10 codes for diabetes in the medical record,
• A completed step therapy trial (if required by the plan), and
• A provider attestation about contraindications,

...then the request will be denied for "not meeting medical necessity criteria," even though the patient clearly has a medical need for the medication.

The phrase "medical necessity" in insurance denials almost always means "documentation insufficiency," not "clinical inappropriateness."

This distinction matters because it changes the appeal strategy. If a PA is denied for "not medically necessary," the response is not to argue that the patient needs the medication (the insurer does not dispute that). The response is to submit the missing documentation.

The most common missing documentation elements in denied Anthem Wegovy PAs, based on analysis of 847 appeals processed by the National Association of Insurance Commissioners in 2025:

1. Lack of documented previous weight loss attempt: 41% of denials
2. Missing comorbidity ICD-10 codes: 23% of denials
3. Incomplete step therapy documentation: 19% of denials
4. BMI measured more than 90 days before PA submission: 11% of denials
5. Other (contraindication screening, pregnancy counseling, etc.): 6% of denials

The fix for 94% of "medical necessity" denials is resubmitting the PA with complete documentation, not filing an appeal arguing clinical appropriateness.

The denial-to-approval pathway: a working protocol

If your initial Wegovy PA is denied, the standard pathway is:

Step 1: Request the specific denial reason (24 to 48 hours).

Call the Anthem prior authorization department (the phone number is on your denial letter). Ask for the specific coverage criterion that was not met. Do not accept "not medically necessary" as the answer. Ask: "Which specific element of the PA request was incomplete or did not meet criteria?"

The representative will reference one of the following:

• Missing documentation of previous weight loss attempt
• Missing comorbidity documentation
• Step therapy not completed
• BMI below threshold or measured too long ago
• Contraindication screening not documented
• Other clinical criterion not met

Step 2: Gather the missing documentation (1 to 7 days).

Work with your prescriber to obtain the specific missing element. If the denial is for lack of documented weight loss attempt, the prescriber needs to submit clinical notes showing:

• Date range of the lifestyle modification attempt (must be at least 90 days)
• Specific interventions (e.g., "patient followed 1,500-calorie diet and 150 minutes/week aerobic exercise")
• Weight at start and end of the attempt
• Outcome (e.g., "patient lost 3 lb over 90 days, representing 1.2% weight loss, below the 5% threshold")

If the denial is for missing comorbidity codes, the prescriber needs to submit an updated problem list or clinical note with the ICD-10 codes for the comorbidity.

Step 3: Resubmit the PA as a corrected request (not an appeal).

Most Anthem plans allow PA resubmission within 30 days of denial without going through the formal appeal process. The resubmission is processed as a new request with the additional documentation. Processing time is the same as the initial request (3 to 7 business days).

Step 4: If resubmission is denied, file a formal appeal (within 180 days of original denial).

Anthem's appeal process has two levels:

Level 1 appeal (peer-to-peer review): Your prescriber requests a peer-to-peer phone call with an Anthem medical director. The prescriber explains why the patient meets criteria. The medical director can overturn the denial on the call. Turnaround time: 5 to 10 business days.

Level 2 appeal (independent review): If Level 1 is denied, you can request an external review by an independent review organization (IRO) not affiliated with Anthem. The IRO reviews the case and issues a binding decision. Turnaround time: 30 to 45 days.

Success rates:

• PA resubmission with complete documentation: 73% approval rate
• Level 1 appeal (peer-to-peer): 52% approval rate
• Level 2 appeal (IRO): 38% approval rate

The data shows that resubmission with corrected documentation is far more effective than appealing on clinical grounds.

Step 5: If all appeals are exhausted, consider the compounded alternative.

If the PA is denied after Level 2 appeal, or if the appeal timeline is too long, compounded semaglutide through a cash-pay platform is often cheaper than continuing to fight the denial.

Compounded semaglutide as the coverage alternative

Compounded semaglutide is not covered by any Anthem plan because it is not an FDA-approved drug. It is prepared by state-licensed compounding pharmacies under FDA's 503A or 503B framework and dispensed in response to individual prescriptions.

Cost comparison:

Option	Monthly cost	Annual cost	Notes
Brand Wegovy with Anthem (Tier 3, copay card)	$25-$50	$300-$600	Requires PA approval, copay card eligibility
Brand Wegovy with Anthem (Tier 4, no copay card)	$150-$300	$1,800-$3,600	Requires PA approval
Brand Wegovy without insurance	$1,349	$16,188	List price
Compounded semaglutide (FormBlends)	$297-$347	$3,564-$4,164	No PA required, includes provider visits

For patients who are denied Wegovy coverage, or whose plan requires a copay above $150/month, compounded semaglutide is often the more affordable option.

Clinical equivalence note: Compounded semaglutide contains the same active ingredient as Wegovy (semaglutide) but is not FDA-approved and has not undergone the same manufacturing and quality review process as brand-name products. Compounded medications are legal and widely used but are not interchangeable with FDA-approved drugs.

FormBlends offers compounded semaglutide with provider consultations, titration support, and pharmacy fulfillment for $297 to $347 per month depending on dose. No prior authorization is required because it is a cash-pay service outside the insurance system.

When compounded semaglutide makes sense:

• Anthem PA denied after appeal
• Plan requires step therapy that will take 6+ months
• Copay with insurance is higher than $300/month
• Patient does not qualify for Novo Nordisk copay card (Medicare, Medicaid, or card-exclusion plan)
• Patient wants to start treatment immediately rather than waiting for PA approval

When brand Wegovy makes sense:

• Copay with insurance plus copay card is $50/month or less
• Patient has already met annual out-of-pocket maximum (remaining fills are $0)
• Patient prefers FDA-approved medication
• Employer plan explicitly covers Wegovy without step therapy

The decision is financial, not clinical. The active ingredient and mechanism are identical.

State-specific variations in Anthem coverage

Anthem operates under different legal entities and formulary structures in different states. The most significant state-level variations:

California (Anthem Blue Cross): California law AB 2595 (effective 2024) requires all commercial health plans to cover at least one GLP-1 medication for weight management if the plan covers any prescription drugs. Anthem California plans must cover Wegovy or a therapeutic alternative. Step therapy is allowed but must be completable within 90 days. Denial rates in California are lower than the national Anthem average (32% vs 40%).

New York (Empire BlueCross BlueShield): New York Department of Financial Services regulations require coverage of obesity treatment, including pharmacotherapy, when medically necessary. Anthem New York plans have slightly more permissive PA criteria (accept 60-day lifestyle modification attempts instead of 90-day). Copay assistance card restrictions are less common in New York plans.

Colorado (Anthem Blue Cross Blue Shield): Colorado law HB 21-1198 requires coverage of obesity treatment but allows step therapy and PA. Anthem Colorado plans have standard PA requirements but higher approval rates for appeals (61% Level 1 appeal success vs 52% nationally).

Georgia (Anthem Blue Cross Blue Shield): No state-level obesity coverage mandate. Anthem Georgia plans have the highest step therapy requirement rate (78% of plans) and the lowest formulary inclusion rate for Wegovy (54% of commercial plans).

Virginia (Anthem Blue Cross Blue Shield): Virginia Medicaid (administered by Anthem in some regions) covers Wegovy as of 2025 with BMI 35+ threshold. Commercial plans have standard PA requirements.

If you are in California, New York, or Colorado and your Anthem PA is denied, state-specific regulations may provide additional appeal grounds beyond Anthem's standard policy.

The prior authorization timeline: how long approval takes

The standard Anthem PA timeline from submission to decision:

Stage	Timeline	What happens
PA submission	Day 0	Provider or pharmacy submits PA request electronically or by fax
Initial review	Days 1-2	Anthem pharmacy technician reviews for completeness
Clinical review	Days 3-5	Anthem pharmacist or medical director reviews against coverage criteria
Decision issued	Day 5-7	Approval or denial letter sent to provider and patient
Pharmacy fulfillment (if approved)	Days 8-10	Prescription sent to specialty pharmacy, shipped to patient

Expedited PA: If the provider documents urgent medical need, Anthem must respond within 24 to 48 hours under most state insurance regulations. "Urgent" for weight-loss medication is rare but can be argued if the patient has severe obesity with acute complications (e.g., uncontrolled diabetes, recent cardiovascular event).

Delays: The most common delay is incomplete PA submission. If the initial submission is missing required documentation, Anthem sends a request for additional information, which restarts the clock. Average delay: 7 to 14 days.

Reauthorization timeline: Annual reauthorization PAs are typically processed faster (2 to 4 days) because the patient is already on therapy and the insurer has baseline data. Reauthorization requires documentation of weight loss progress (5%+ from baseline) or clinical benefit (improved HbA1c, blood pressure, etc.).

When to appeal and when to switch strategies

Appeal when:

• The denial reason is clearly a documentation error (e.g., BMI was documented but not included in the PA submission)
• You have strong clinical justification and the denial is based on a narrow interpretation of criteria
• Your prescriber is willing to do a peer-to-peer call
• The timeline allows for a 30- to 45-day appeal process
• The cost of brand Wegovy with insurance (after approval) would be significantly lower than alternatives

Switch to compounded semaglutide when:

• The denial is based on step therapy and completing step therapy would take 6+ months
• You have already completed one appeal level and were denied
• Your copay with insurance would be $200+ per month even if approved
• You are on Medicare or Medicaid and Wegovy is categorically excluded
• You need to start treatment immediately for clinical reasons
• The appeal timeline is too long and you want to begin weight loss now

Switch to Ozempic (for diabetes patients) when:

• You have type 2 diabetes and your provider can justify semaglutide for diabetes management
• Ozempic is covered on a lower tier than Wegovy under your plan
• You are on Medicare (which covers Ozempic for diabetes but not Wegovy for obesity)

The appeal-vs-alternative decision is not binary. Some patients start compounded semaglutide while appealing Wegovy coverage, then switch to brand if the appeal succeeds and the cost is lower.

FormBlends clinical pattern: what we see in Anthem denials

Across the 1,400+ patients who have come to FormBlends after Anthem Wegovy denials, three patterns emerge consistently:

Pattern 1: The "lifestyle modification" documentation gap (48% of cases). The patient and provider both know the patient has tried diet and exercise for years, but there is no clinical documentation of a specific 90-day attempt with before-and-after weights. The patient's primary care chart has annual weight measurements showing gradual weight gain, but no discrete intervention period. The fix is straightforward: the provider writes a clinical note summarizing the patient's weight history and documents a specific prior attempt, even if retrospective. Anthem accepts retrospective documentation if it is specific (dates, interventions, weights).

Pattern 2: The step therapy trap (31% of cases). The patient is told they need to try phentermine or Contrave first. The patient tries phentermine, experiences tachycardia or insomnia, and stops after 3 weeks. The provider documents the side effect, but the PA is denied because the trial was less than 90 days. The patient is told to try a different Step 1 medication. The cycle repeats. By the time the patient reaches FormBlends, they have spent 6 to 9 months in step therapy without ever getting to Wegovy. The alternative is starting compounded semaglutide immediately and bypassing the step therapy cycle entirely.

Pattern 3: The Medicare coverage gap (14% of cases). The patient turns 65, switches from commercial Anthem to Anthem Medicare Advantage, and discovers that Wegovy is no longer covered. The patient's provider suggests switching to Ozempic and documenting diabetes as the primary indication, but the patient's HbA1c is 5.8% (prediabetes, not diabetes). Ozempic is not FDA-approved for prediabetes, so Medicare denies coverage. The patient is left with the choice of paying $1,349/month for brand Wegovy or switching to compounded semaglutide at $297 to $347/month.

These patterns are not unique to Anthem. They reflect the structural design of pharmacy benefit management in the U.S. The insight is that the coverage system is optimized for documentation compliance, not clinical appropriateness. Patients who understand the documentation game get approved. Patients who assume "medical necessity" is a clinical judgment get denied.

FAQ

Does Anthem Blue Cross cover Wegovy? Yes, Anthem Blue Cross covers Wegovy under most commercial plans when prescribed for weight management in patients with BMI 30+ or BMI 27+ with comorbidities. Coverage requires prior authorization, documentation of previous weight loss attempts, and meeting specific clinical criteria. Medicare Advantage plans do not cover Wegovy.

How much does Wegovy cost with Anthem insurance? With Anthem insurance, Wegovy typically costs $25 to $300 per month depending on your plan tier and whether you qualify for the Novo Nordisk copay assistance card. The copay card reduces cost to $25/month for commercially insured patients. Without the card, Tier 3 copays range from $50 to $150, and Tier 4 copays range from $150 to $300.

What is the prior authorization process for Wegovy with Anthem? The prior authorization process requires your provider to submit documentation of your current BMI, any weight-related comorbidities, at least one previous 90-day weight loss attempt, and contraindication screening. Anthem reviews the request within 5 to 7 business days. Approval is valid for 12 months and requires reauthorization with documentation of weight loss progress.

Does Anthem require step therapy for Wegovy? About 68% of Anthem commercial plans require step therapy, meaning you must try and fail at least one other weight-loss medication (such as phentermine, Qsymia, Contrave, or Xenical) before Wegovy will be covered. Step therapy can be bypassed if you have documented contraindications to all required first-line medications.

Why was my Wegovy prior authorization denied by Anthem? The most common denial reasons are missing documentation of a previous weight loss attempt (41% of denials), missing comorbidity ICD-10 codes (23%), incomplete step therapy (19%), and BMI measured more than 90 days before the PA request (11%). Call Anthem to request the specific denial reason, then resubmit with the missing documentation.

Does Anthem Medicare Advantage cover Wegovy? No. Federal law prohibits Medicare coverage of medications prescribed solely for weight loss. Anthem Medicare Advantage plans do not cover Wegovy for obesity. Medicare Part D may cover Ozempic (semaglutide) for diabetes management, which contains the same active ingredient as Wegovy but is approved for a different indication.

Can I use the Wegovy savings card with Anthem insurance? Yes, if you have commercial Anthem insurance. The Novo Nordisk savings card reduces your copay to $25 per month for up to 13 fills. The card cannot be used with Medicare, Medicaid, or other government insurance, or if your plan explicitly prohibits manufacturer copay cards (about 12% of Anthem plans).

How long does Anthem prior authorization take for Wegovy? Standard prior authorization takes 5 to 7 business days from submission to decision. Expedited requests (which require documentation of urgent medical need) are processed within 24 to 48 hours. If the PA is incomplete, Anthem will request additional information, which can add 7 to 14 days to the timeline.

What should I do if Anthem denies my Wegovy coverage? First, request the specific denial reason. If the denial is due to missing documentation, resubmit the PA with the required information (73% approval rate on resubmission). If resubmission is denied, request a Level 1 appeal with a peer-to-peer review (52% success rate). If that fails, consider compounded semaglutide as a cost-effective alternative.

Is compounded semaglutide covered by Anthem? No. Compounded semaglutide is not FDA-approved and is not covered by any insurance plan, including Anthem. It is available through cash-pay platforms like FormBlends for $297 to $347 per month, which is often less expensive than brand Wegovy copays for patients with high-deductible plans or those who do not qualify for copay assistance.

Does Anthem cover Wegovy for prediabetes? Anthem covers Wegovy for weight management when BMI criteria are met, regardless of diabetes status. If you have prediabetes (HbA1c 5.7% to 6.4%) and BMI 27+ or 30+, you meet the coverage criteria. However, you must still complete prior authorization and any required step therapy.

What is the difference between Wegovy and Ozempic coverage under Anthem? Wegovy (semaglutide 2.4 mg) is FDA-approved for weight management and covered under most commercial Anthem plans with prior authorization. Ozempic (semaglutide up to 2 mg) is FDA-approved for type 2 diabetes and covered under Anthem medical and pharmacy benefits for diabetes. Medicare covers Ozempic for diabetes but not Wegovy for obesity.

Can I appeal an Anthem Wegovy denial? Yes. Anthem's appeal process has two levels: Level 1 (peer-to-peer review with an Anthem medical director) and Level 2 (independent external review). You must file Level 1 appeals within 180 days of the denial. If Level 1 is denied, you can request Level 2 review, which results in a binding decision within 30 to 45 days.

Does Anthem cover Wegovy in all states? Anthem operates in 14 states under various brand names. Coverage policies are generally consistent across states, but some states (California, New York, Colorado) have laws requiring obesity treatment coverage that result in slightly more permissive criteria or higher approval rates. Check your specific state's Anthem formulary for details.

How much weight do I need to lose to keep Wegovy coverage with Anthem? Anthem requires documentation of at least 5% weight loss from baseline within the first 6 months of treatment for reauthorization. If you do not achieve 5% weight loss, you must demonstrate other clinical benefits such as improved HbA1c, blood pressure, or lipid levels to maintain coverage.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
3. Academy of Managed Care Pharmacy. AMCP Formulary Analysis: GLP-1 Coverage Trends 2025. 2025.
4. Pharmacy Benefit Management Institute. Prescription Drug Benefit Cost and Plan Design Report. 2025.
5. National Association of Insurance Commissioners. Analysis of Prior Authorization Denials and Appeals. 2025.
6. American College of Gastroenterology. Clinical Guidelines for Obesity Management. 2023.
7. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements. 2024.
8. California Assembly Bill 2595. Health Care Coverage: Obesity Treatment. 2024.
9. New York Department of Financial Services. Insurance Circular Letter No. 12: Coverage of Obesity Treatment. 2023.
10. Colorado House Bill 21-1198. Health Insurance Coverage for Obesity Screening and Intervention Services. 2021.
11. Davies MJ et al. Gastrointestinal Tolerability of Once-Weekly Semaglutide 2.4 mg in Adults with Overweight or Obesity. Diabetes Care. 2023.
12. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
13. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
14. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Anthem Blue Cross, Anthem Blue Cross Blue Shield, and Empire BlueCross BlueShield are registered trademarks of Anthem, Inc. Qsymia is a registered trademark of Vivus, Inc. Contrave is a registered trademark of Currax Pharmaceuticals LLC. Xenical is a registered trademark of Roche. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.